Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Forst

Showing results (111-120 of 148) with videos related to

Pageof 15
Sort By:
Clinical Chemistry and Laboratory Medicine|May 10, 2006
Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitusAndreas Pfützner, Eberhard Standl, Hermann-Josef Strotmann, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Endothelial function and arterial stiffness in uncomplicated type 1 diabetes and healthy controls and the impact of insulin on these parameters during an euglycemic clampBirgit Wilhelm, Matthias M Weber, Hans Peter Kreisselmeier, et al.
Lancet (London, England)|July 15, 2014
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialKathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, et al.
Journal of Diabetes Science and Technology|April 30, 2011
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix studyThomas Schöndorf, Petra B Musholt, Cloth Hohberg, et al.
Diabetes Technology & Therapeutics|August 18, 2017
Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Cynthia Harris, Thomas Forst, Tim Heise, et al.
Clinical Laboratory|November 21, 2012
Development and validation of a rapid and reliable method for TPMT genotyping using real-time PCRMarion Lorenz, Alexander Weise, Stefan Prause, et al.
Diabetes Care|February 13, 2008
Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial stateClothilde Hohberg, Thomas Forst, Martin Larbig, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|May 5, 2018
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic StudyThomas Forst, Mohammed Khaled Alghdban, Annelie Fischer, et al.
Clinical Science (London, England : 1979)|June 1, 2010
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitusThomas Forst, Matthias M Weber, Mirjam Löbig, et al.
Diabetes & Vascular Disease Research|October 30, 2008
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular riskThomas Forst, Birgit Wilhelm, Andreas Pfützner, et al.
Pageof 15

Showing results (111-120 of 148) with videos related to

Sort By:
Pageof 15
Clinical Chemistry and Laboratory Medicine|May 10, 2006
Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitusAndreas Pfützner, Eberhard Standl, Hermann-Josef Strotmann, et al.
Journal of Diabetes Science and Technology|November 4, 2009
Endothelial function and arterial stiffness in uncomplicated type 1 diabetes and healthy controls and the impact of insulin on these parameters during an euglycemic clampBirgit Wilhelm, Matthias M Weber, Hans Peter Kreisselmeier, et al.
Lancet (London, England)|July 15, 2014
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trialKathleen M Dungan, Santiago Tofé Povedano, Thomas Forst, et al.
Journal of Diabetes Science and Technology|April 30, 2011
The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix studyThomas Schöndorf, Petra B Musholt, Cloth Hohberg, et al.
Diabetes Technology & Therapeutics|August 18, 2017
Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8Cynthia Harris, Thomas Forst, Tim Heise, et al.
Clinical Laboratory|November 21, 2012
Development and validation of a rapid and reliable method for TPMT genotyping using real-time PCRMarion Lorenz, Alexander Weise, Stefan Prause, et al.
Diabetes Care|February 13, 2008
Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial stateClothilde Hohberg, Thomas Forst, Martin Larbig, et al.
Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme|May 5, 2018
Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic StudyThomas Forst, Mohammed Khaled Alghdban, Annelie Fischer, et al.
Clinical Science (London, England : 1979)|June 1, 2010
Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitusThomas Forst, Matthias M Weber, Mirjam Löbig, et al.
Diabetes & Vascular Disease Research|October 30, 2008
Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular riskThomas Forst, Birgit Wilhelm, Andreas Pfützner, et al.
Pageof 15